Sareum (LON:SAR) Releases Earnings Results

Sareum (LON:SAR) posted its quarterly earnings data on Tuesday. The company reported GBX (0.90) (($0.01)) EPS for the quarter, Digital Look Earnings reports.

Sareum Trading Up 9.6 %

Shares of SAR stock traded up GBX 1.15 ($0.01) on Thursday, hitting GBX 13.15 ($0.17). 1,004,110 shares of the stock were exchanged, compared to its average volume of 421,408. The firm’s 50 day moving average is GBX 17.82 and its two-hundred day moving average is GBX 23.19. Sareum has a one year low of GBX 10 ($0.13) and a one year high of GBX 52.50 ($0.68). The firm has a market capitalization of £16.43 million, a PE ratio of -3.11 and a beta of -1.08.

Insider Activity at Sareum

In related news, insider Stephen Parker purchased 84,033 shares of the firm’s stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average cost of GBX 12 ($0.15) per share, for a total transaction of £10,083.96 ($12,983.08). 5.02% of the stock is currently owned by company insiders.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.